A phase 3 trial testing two long licensed and inexpensive drugs after lacunar stroke is open and recruiting in the United Kingdom, with thinking and memory as its main measure of success. The LACunar Intervention Trial 3 (LACI-3), registered as ISRCTN44436843 and funded by the National Institute for Health and Care Research Health Technology Assessment programme, aims to recruit 1,300 participants from 55 to 60 UK centres. According to the trial team's design summary presented at the European Stroke Organisation Conference and published in the European Stroke Journal in May 2026, LACI-3 is an investigator led, open label, blinded outcome, two by two partial factorial trial of oral isosorbide mononitrate (50mg once daily or equivalent) and/or cilostazol (100mg twice daily), or neither, on top of guideline stroke prevention, given for 18 months. The primary outcome is a seven level DSM-5 cognitive score at 18 months. Total trial duration is 52 months, and the trial is being run with UK Medicines and Healthcare products Regulatory Agency scientific advice to support any future licensing. The chief investigator is Professor Joanna Wardlaw of the University of Edinburgh.
Lacunar strokes account for about a quarter of ischaemic strokes and are caused mostly by disease of the brain's smallest blood vessels, which the trial's public materials say affects roughly 35,000 people a year in the UK. Cerebral small vessel disease is the most common cause of vascular cognitive impairment and contributes to vascular and mixed dementias, and there is no specific treatment for it. Both trial drugs are already licensed for other conditions, isosorbide mononitrate for angina and cilostazol for intermittent claudication, which is why researchers describe LACI-3 as a repurposing trial: if it works, the medicines already exist, are off patent and are cheap.
The evidence behind it is preliminary. LACI-1 enrolled 57 patients and LACI-2 enrolled 363 of a planned 400 at 26 UK centres between February 2018 and May 2021 with 12 month follow up; together they established feasibility, tolerability and safety, not efficacy. In LACI-2, reported in JAMA Neurology in May 2023, neither drug alone reduced the composite outcome (isosorbide mononitrate adjusted hazard ratio 0.80, 95% confidence interval 0.59 to 1.09; cilostazol 0.77, 0.57 to 1.05, in 297 patients). Secondary analyses in smaller subgroups suggested isosorbide mononitrate reduced recurrent stroke (adjusted odds ratio 0.23, 0.07 to 0.74, in 353 patients) and any cognitive impairment (0.55, 0.36 to 0.86, in 308 patients), and that the combination reduced the composite (adjusted hazard ratio 0.58, 0.36 to 0.92) and any cognitive impairment (0.44, 0.23 to 0.85) in 153 patients. The authors themselves called for large phase 3 testing; a 6 month analysis posted as a preprint on medRxiv in August 2025, which has not completed peer review, reported a similar pattern.
The counterpoint is that hypothesis generating signals from a feasibility trial of a few hundred people, some based on subgroups of 153, frequently do not survive an adequately powered test, and LACI-3 is open label, which leaves scope for reporting bias even with blinded outcome assessment. Both drugs have well recognised side effects, including headache, palpitations, dizziness and loose stools, which LACI-2 tracked deliberately. Because the small vessel field currently has no other active phase 3 programme of this kind, a null result would remove the leading near term candidate and send attention back to earlier stage work. The registry entry sets an intention to publish date of 31 December 2029, and eligibility for any trial is a matter for a person's own stroke team.